GlobeNewswire Inc.··Revolution MedicinesRevolution Medicines' Daraxonrasib Achieves NEJM Publication on Pancreatic Cancer Progress
Revolution Medicines published Phase 1/2 daraxonrasib data in NEJM, demonstrating promising activity in RAS mutant pancreatic cancer and supporting Phase 3 trial initiation.
RVMDRVMDWclinical trial resultspancreatic cancer